FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308378511> ?p ?o ?g. }

• W4308378511 abstract "<h3>Background</h3> Macrophages patrol intercellular spaces mainly through their receptor SIRPa, which interacts with CD47 on target cells. Such interaction elicits a ‘do not eat’ signal and spares the target cell from being phagocytosed. Many cancers take advantage of this mechanism via overexpressing CD47 to evade immune surveillance. Therefore, blocking SIRPa-CD47 interaction represents a promising approach for anti-cancer therapy. Numerous anti-CD47 antibodies and SIRPa fusion proteins have been developed with therapeutic potential, but their clinical progress was hindered by either severe side effects or lack of appreciable efficacy. To overcome this deficiency, we aim to produce a SIRPa-fusion biologic that exhibits superior efficacy against multiple hematological and solid malignancies while maintaining good safety profiles and protein stability. <h3>Methods</h3> Using display technology combined with structure-guided protein engineering, we identified several SIRPa mutants that exhibited significant CD47-blocking activities and phagocytosis against tumor cells while minimizing side effects on CD47-expressing normal cells. To assess the impact of CD47 blockade on macrophages within the tumor microenvironment, these novel mutants were evaluated in multiple human tumor xenograft mouse models and compared with selected anti-CD47 monoclonal antibodies and/or SIRPa fusion proteins currently being investigated in clinical trials. The leading candidates were further analyzed for their respective CMC profiles to ensure good protein stability and straightforward manufacturability. <h3>Results</h3> In comparison with prominent clinical candidates targeting the CD47 pathway (Magrolimab, TTI-622, ALX148, TJC4, IMM01), HCB101 demonstrated superior or compatible CD47-blocking activities; meanwhile, it triggered strong phagocytosis against tumor cells but not red blood cells. In all 7 human tumor xenograft NOD/SCID mouse models that we investigated, HCB101 consistently showed excellent efficacy against hematological and solid tumors as monotherapy, with tumor growth inhibition index (TGI) ranging from 60-100% at the dose of 0.5-10mg/kg over placebo. We observed an increase in the M1/M2 macrophage ratio and a reduction of CD24 expression in certain cases after the treatment with HCB101. This could partially account for its superior anti-tumor efficacy. There was no apparent adverse reaction observed during the exploratory cynomolgus monkey toxicology studies, suggesting a good safety profile of HCB101. <h3>Conclusions</h3> Compared to relevant clinical candidates, HCB101 exhibits superior efficacy in 7 different CDX models of hematological and solid malignancies while maintaining good safety profiles. A highly effective blockade of the CD47-SIRPa pathway by HCB101 leads to robust pre-clinical results. Moreover, it exhibits outstanding protein stability and manufactural characteristics for large-scale production. Clinical development of HCB101 is currently underway both as monotherapy and in combination." @default.
• W4308378511 created "2022-11-11" @default.
• W4308378511 creator A5000459169 @default.
• W4308378511 creator A5013506995 @default.
• W4308378511 creator A5017843718 @default.
• W4308378511 creator A5024402074 @default.
• W4308378511 creator A5024714647 @default.
• W4308378511 creator A5026701920 @default.
• W4308378511 creator A5035342455 @default.
• W4308378511 creator A5036766804 @default.
• W4308378511 creator A5060336265 @default.
• W4308378511 creator A5063750116 @default.
• W4308378511 creator A5066796679 @default.
• W4308378511 creator A5074829021 @default.
• W4308378511 creator A5081079566 @default.
• W4308378511 creator A5081352628 @default.
• W4308378511 creator A5083054612 @default.
• W4308378511 creator A5090079108 @default.
• W4308378511 date "2022-11-01" @default.
• W4308378511 modified "2023-09-26" @default.
• W4308378511 title "496 HCB101: A safe and effective ligand trap therapeutic targeting the CD47-SIRPa signaling pathway for cancer treatment" @default.
• W4308378511 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0496" @default.
• W4308378511 hasPublicationYear "2022" @default.
• W4308378511 type Work @default.
• W4308378511 citedByCount "0" @default.
• W4308378511 crossrefType "proceedings-article" @default.
• W4308378511 hasAuthorship W4308378511A5000459169 @default.
• W4308378511 hasAuthorship W4308378511A5013506995 @default.
• W4308378511 hasAuthorship W4308378511A5017843718 @default.
• W4308378511 hasAuthorship W4308378511A5024402074 @default.
• W4308378511 hasAuthorship W4308378511A5024714647 @default.
• W4308378511 hasAuthorship W4308378511A5026701920 @default.
• W4308378511 hasAuthorship W4308378511A5035342455 @default.
• W4308378511 hasAuthorship W4308378511A5036766804 @default.
• W4308378511 hasAuthorship W4308378511A5060336265 @default.
• W4308378511 hasAuthorship W4308378511A5063750116 @default.
• W4308378511 hasAuthorship W4308378511A5066796679 @default.
• W4308378511 hasAuthorship W4308378511A5074829021 @default.
• W4308378511 hasAuthorship W4308378511A5081079566 @default.
• W4308378511 hasAuthorship W4308378511A5081352628 @default.
• W4308378511 hasAuthorship W4308378511A5083054612 @default.
• W4308378511 hasAuthorship W4308378511A5090079108 @default.
• W4308378511 hasBestOaLocation W43083785111 @default.
• W4308378511 hasConcept C104317684 @default.
• W4308378511 hasConcept C121608353 @default.
• W4308378511 hasConcept C123894998 @default.
• W4308378511 hasConcept C159654299 @default.
• W4308378511 hasConcept C160448771 @default.
• W4308378511 hasConcept C185592680 @default.
• W4308378511 hasConcept C203014093 @default.
• W4308378511 hasConcept C2780104668 @default.
• W4308378511 hasConcept C40767141 @default.
• W4308378511 hasConcept C502942594 @default.
• W4308378511 hasConcept C542903549 @default.
• W4308378511 hasConcept C54355233 @default.
• W4308378511 hasConcept C55493867 @default.
• W4308378511 hasConcept C86803240 @default.
• W4308378511 hasConcept C8891405 @default.
• W4308378511 hasConcept C95444343 @default.
• W4308378511 hasConcept C96232424 @default.
• W4308378511 hasConceptScore W4308378511C104317684 @default.
• W4308378511 hasConceptScore W4308378511C121608353 @default.
• W4308378511 hasConceptScore W4308378511C123894998 @default.
• W4308378511 hasConceptScore W4308378511C159654299 @default.
• W4308378511 hasConceptScore W4308378511C160448771 @default.
• W4308378511 hasConceptScore W4308378511C185592680 @default.
• W4308378511 hasConceptScore W4308378511C203014093 @default.
• W4308378511 hasConceptScore W4308378511C2780104668 @default.
• W4308378511 hasConceptScore W4308378511C40767141 @default.
• W4308378511 hasConceptScore W4308378511C502942594 @default.
• W4308378511 hasConceptScore W4308378511C542903549 @default.
• W4308378511 hasConceptScore W4308378511C54355233 @default.
• W4308378511 hasConceptScore W4308378511C55493867 @default.
• W4308378511 hasConceptScore W4308378511C86803240 @default.
• W4308378511 hasConceptScore W4308378511C8891405 @default.
• W4308378511 hasConceptScore W4308378511C95444343 @default.
• W4308378511 hasConceptScore W4308378511C96232424 @default.
• W4308378511 hasLocation W43083785111 @default.
• W4308378511 hasOpenAccess W4308378511 @default.
• W4308378511 hasPrimaryLocation W43083785111 @default.
• W4308378511 hasRelatedWork W1572283981 @default.
• W4308378511 hasRelatedWork W1986617066 @default.
• W4308378511 hasRelatedWork W2411114470 @default.
• W4308378511 hasRelatedWork W2615829490 @default.
• W4308378511 hasRelatedWork W3048051248 @default.
• W4308378511 hasRelatedWork W3087378297 @default.
• W4308378511 hasRelatedWork W4200563690 @default.
• W4308378511 hasRelatedWork W4283731173 @default.
• W4308378511 hasRelatedWork W4291367166 @default.
• W4308378511 hasRelatedWork W4367181942 @default.
• W4308378511 isParatext "false" @default.
• W4308378511 isRetracted "false" @default.
• W4308378511 workType "article" @default.